Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion

Key Takeaways

• Chiesi pays $27 per share, 40% premium over KalVista's close
• Sebetralstat generated $49 million U.S. sales in 2025 launch
• Deal values KalVista at 14.1× its 2025 sales
• Acquisition supports Chiesi's goal of $6.5 billion revenue by 2030

Pulse Analysis

The Chiesi‑KalVista transaction marks one of the largest European‑to‑U.S. biopharma deals of 2026, underscoring a broader trend of cross‑border M&A aimed at securing innovative rare‑disease assets. By acquiring KalVista, Chiesi not only gains sebetralstat—a first‑in‑class oral inhibitor for hereditary angioedema—but also inherits a pipeline of protease inhibitors that could address other unmet indications. This strategic fit aligns with Chiesi’s diversification beyond its traditional respiratory portfolio, providing a foothold in the lucrative specialty‑care segment where oral therapies are increasingly favored for patient convenience and adherence.

Sebetralstat’s rapid market uptake, delivering $49 million in U.S. sales within months of its July 2025 launch, demonstrates strong payer acceptance and a clear unmet need for on‑demand HAE treatment. The drug’s approval across the U.S., EU, U.K., and Japan, coupled with ongoing pediatric studies, positions it for global scale. For investors, the 14.1‑times sales multiple reflects confidence in the product’s growth trajectory and the broader value of KalVista’s R&D platform, which could yield additional revenue streams as later‑stage candidates advance.

Financially, the $1.9 billion price tag—equivalent to roughly $6.5 billion in projected revenue for Chiesi by 2030—highlights the premium placed on rare‑disease innovation. Advisors such as Lazard and Ropes & Gray facilitated a smooth transaction, while the anticipated Q3 2026 close aligns with Chiesi’s fiscal planning. The acquisition not only bolsters Chiesi’s U.S. presence but also signals to the market that European biopharma firms are willing to invest heavily to capture high‑margin, specialty‑care opportunities in the United States.